Health Canada Approves OPDIVO® plus YERVOY® as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
AbbVie to Present Analysis Evaluating Continuous RINVOQ® Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of 'Eye-Bulging' Tumor
Psychedelics Investing Silo Wellness Partners with Mushe Inc. to Establish First Legal Brick & Mortar Psychedelic and Functional Mushroom Shop in the Western Hemisphere
Medical Device Investing Avisa Diagnostics Appoints Barbara Bunger, PhD as Vice President, Clinical Development
New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress
Medical Device Investing Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE
Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain MetastasisÂ
